Use of antihypertensive drugs before and after the valsartan recall on July 9, 2018
| No. of drugs dispensed (% change)* | ||||||
|---|---|---|---|---|---|---|
| All ARBs | Valsartan | Non-valsartan ARBs | ACE inhibitors | Other hypertensives† | Total | |
| June 2018 | 1 577 509 | 362 231 | 1 215 278 | 1 939 144 | 4 673 711 | 8 190 364 |
| September 2018‡ | 1 545 591 (−2.0) | 152 892 (−57.8) | 1 392 699 (14.6) | 1 835 269 (−5.4) | 4 568 105 (−2.3) | 7 948 965 (−2.9) |
| December 2019§ | 1 753 924 (13.5) | 173 224 (13.3) | 1 580 700 (13.5) | 1 976 285 (7.7) | 5 365 868 (17.5) | 9 096 077 (14.4) |
Note: ACE = angiotensin converting enzyme, ARB = angiotensin receptor blockers.
↵* Monthly number of prescriptions dispensed.
↵† Other antihypertensives include calcium channel blockers, β-blockers, diuretics.
↵‡ Percent change from June 2018 to September 2018.
↵§ Percent change from September 2018 to December 2019.